Written questions by McKee.

What discussions his Department has had with Scottish local authorities on the delivery of UK Government-funded projects.

Awaiting answer.

By what date liquid biopsy technologies will be routinely available for brain tumour patients across the NHS; how many additional patients are expected to gain access to targeted or repurposed treatments as a result; what barriers currently prevent access to such treatments where the same mutation is already treated in another cancer type; and who will be responsible for working to remove those barriers.

Awaiting answer.

What progress has been made on simplifying the rail fares and ticketing system.

Awaiting answer.

What proportion of direct procurement expenditure was awarded to UK small and medium-sized enterprises in the last financial year.

Awaiting answer.

What key performance indicators and outcome measures will be used to assess the effectiveness of the National Cancer Board; who will be responsible for overseeing delivery of those outcomes; where information on the Board's performance will be published; and how the interests of brain cancer patients will be represented in the Board's decision-making.

Awaiting answer.

Which recommendations relating to the cancer workforce from previous workforce reviews, task and finish groups, and National Cancer Board workstreams remain outstanding; what assessment has been made of the impact of those outstanding recommendations on brain cancer patients; and how the National Clinical Lead for Rare Cancers, the Rare Cancer Speciality Lead and the National Cancer Board will support their implementation.

Awaiting answer.

Which visa categories currently have the largest number of outstanding applications.

Awaiting answer.

What assessment he has made of the effectiveness of cross-government coordination on national security priorities.

Awaiting answer.

What assessment he has made of the average time taken for a reservist to complete the Armed Forces recruitment process from initial application to enlistment.

Awaiting answer.

What proportion of reservists have been mobilised for operations in each of the last five years.

Awaiting answer.

What assessment he has made of the potential impact of UK Government investment programmes on communities in Scotland.

Awaiting answer.

What measurable improvements in (a) workforce capacity, (b) research activity, (c) clinical trial access, (d) speed of diagnosis and (e) patient outcomes are expected as a result of the work of the National Clinical Lead for Rare Cancers, the Rare Cancer Specialty Lead and the National Cancer Board; how those improvements are expected to build on previous arrangements; by what dates they are expected to be achieved; and what arrangements are in place to monitor progress and ensure accountability.

Awaiting answer.

Whether his department will consider the appointment of a specific National Clinical Lead for Brain Cancers.

Awaiting answer.

Whether the (a) National Clinical Lead for Rare Cancers and (b) Rare Cancer Specialty Lead have been appointed; if so, on what date, and against which National Cancer Plan commitments they will be assessed; and if not, when appointments are expected to be made and who is currently undertaking those functions.

Awaiting answer.

Innovation and Technology, what assessment she has made of the UK’s position compared with other advanced economies in urban 5G deployment.

Awaiting answer.

Media and Sport, what discussions she has had with Ofcom on the potential impact of consolidation in the UK broadcasting sector on competition.

Awaiting answer.

What assessment she has made of progress in reducing the number of outstanding visa and asylum applications since July 2024.

Awaiting answer.

How many exercises testing national resilience arrangements have been conducted in each of the last five years.

Awaiting answer.

What steps her Department is taking to reduce the risk of widespread flight disruption caused by air traffic control failures.

Awaiting answer.

What formal mechanisms are in place to ensure that the views of patients, families and brain cancer patient advocacy organisations are reflected in the work of the National Clinical Lead for Rare Cancers, the Rare Cancer Speciality Lead and the National Cancer Board; and how those bodies will be expected to respond to, and report on, the concerns raised through those mechanisms.

Awaiting answer.